Terms: = Gastric cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4
63 results:
1. Metastatic Lymph Node 64 (MLN64) Expression in gastric cancer: The Clinical and Molecular Implications in Drug Resistance.
Li AX; Zeng JJ; Khan E; Dou QP; Zhuang X; Ji EK; Ruge F; Martin TA; Jia S; Jiang WG
Cancer Genomics Proteomics; 2024; 21(1):30-40. PubMed ID: 38151289
[TBL] [Abstract] [Full Text] [Related]
2. Nanoplatform-based analysis for the detection of HER3 and her4 for gastric cancer diagnosis.
Gheorghe DC; Stefan-Van Staden RI; Ilie-Mihai RM; Sfirloaga P
Nanotechnology; 2023 Jun; 34(34):. PubMed ID: 37253333
[TBL] [Abstract] [Full Text] [Related]
3. Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract.
Wu H; Yu Z; Liu Y; Guo L; Teng L; Guo L; Liang L; Wang J; Gao J; Li R; Yang L; Nie X; Su D; Liang Z
Cancer Commun (Lond); 2022 Dec; 42(12):1367-1386. PubMed ID: 36264285
[TBL] [Abstract] [Full Text] [Related]
4. A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study.
Salawu A; Hansen AR; Spreafico A; Al-Ezzi E; Webster S; Bedard PL; Doi J; Wang L; Siu LL; Abdul Razak AR
Target Oncol; 2022 May; 17(3):271-281. PubMed ID: 35635640
[TBL] [Abstract] [Full Text] [Related]
5. The HER family as therapeutic targets in colorectal cancer.
Ye P; Wang Y; Li R; Chen W; Wan L; Cai P
Crit Rev Oncol Hematol; 2022 Jun; 174():103681. PubMed ID: 35462030
[TBL] [Abstract] [Full Text] [Related]
6. Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal cancer: A Review.
Strickler JH; Yoshino T; Graham RP; Siena S; Bekaii-Saab T
JAMA Oncol; 2022 May; 8(5):760-769. PubMed ID: 35238866
[TBL] [Abstract] [Full Text] [Related]
7. Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors.
Lee MX; Wong ALA; Ow S; Sundar R; Tan DSP; Soo RA; Chee CE; Lim JSJ; Yong WP; Lim SE; Goh BC; Wang L; Lee SC
Target Oncol; 2022 Mar; 17(2):141-151. PubMed ID: 35195837
[TBL] [Abstract] [Full Text] [Related]
8. The Yin and Yang of erbb4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
9. Anti‑HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma.
Asano T; Ohishi T; Takei J; Nakamura T; Nanamiya R; Hosono H; Tanaka T; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184091
[TBL] [Abstract] [Full Text] [Related]
10. Validity of claims-based algorithms for selected cancers in Japan: Results from the VALIDATE-J study.
de Luise C; Sugiyama N; Morishima T; Higuchi T; Katayama K; Nakamura S; Chen H; Nonnenmacher E; Hase R; Jinno S; Kinjo M; Suzuki D; Tanaka Y; Setoguchi S
Pharmacoepidemiol Drug Saf; 2021 Sep; 30(9):1153-1161. PubMed ID: 33960542
[TBL] [Abstract] [Full Text] [Related]
11. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
Mezynski MJ; Farrelly AM; Cremona M; Carr A; Morgan C; Workman J; Armstrong P; McAuley J; Madden S; Fay J; Sheehan KM; Kay EW; Holohan C; Elamin Y; Rafee S; Morris PG; Breathnach O; Grogan L; Hennessy BT; Toomey S
J Transl Med; 2021 May; 19(1):184. PubMed ID: 33933113
[TBL] [Abstract] [Full Text] [Related]
12. Clonal Architectures Predict Clinical Outcome in gastric Adenocarcinoma Based on Genomic Variation, Tumor Evolution, and Heterogeneity.
Ren C; Wu C; Wang N; Lian C; Yang C
Cell Transplant; 2021; 30():963689721989606. PubMed ID: 33900127
[TBL] [Abstract] [Full Text] [Related]
13. MicroRNA-936/erbb4/Akt axis exhibits anticancer properties of gastric cancer through inhibition of cell proliferation, migration, and invasion.
Liu S; Gong Y; Xu XD; Shen H; Gao S; Bao HD; Guo SB; Yu XF; Gong J
Kaohsiung J Med Sci; 2021 Feb; 37(2):111-120. PubMed ID: 33021020
[TBL] [Abstract] [Full Text] [Related]
14. Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry.
Cotes Sanchís A; Gallego J; Hernandez R; Arrazubi V; Custodio A; Cano JM; Aguado G; Macias I; Lopez C; López F; Visa L; Garrido M; Martínez Lago N; Fernández Montes A; Limón ML; Azkárate A; Pimentel P; Reguera P; Ramchandani A; Cacho JD; Martín Carnicero A; Granja M; Martín Richard M; Hernández Pérez C; Hurtado A; Serra O; Buxo E; Vidal Tocino R; Jimenez-Fonseca P; Carmona-Bayonas A
PLoS One; 2020; 15(7):e0235848. PubMed ID: 32735623
[TBL] [Abstract] [Full Text] [Related]
15. Allicin suppresses growth and metastasis of gastric carcinoma: the key role of microRNA-383-5p-mediated inhibition of erbb4 signaling.
Lv Q; Xia Q; Li J; Wang Z
Biosci Biotechnol Biochem; 2020 Oct; 84(10):1997-2004. PubMed ID: 32597323
[TBL] [Abstract] [Full Text] [Related]
16. HOTAIR Competitively Binds MiRNA330 as a Molecular Sponge to Increase the Resistance of gastric cancer to Trastuzumab.
Bie L; Luo S; Li D; Wei Y; Mu Y; Chen X; Wang S; Guo P; Lu X
Curr Cancer Drug Targets; 2020; 20(9):700-709. PubMed ID: 32364078
[TBL] [Abstract] [Full Text] [Related]
17. The role of erbb4 in cancer.
Segers VFM; Dugaucquier L; Feyen E; Shakeri H; De Keulenaer GW
Cell Oncol (Dordr); 2020 Jun; 43(3):335-352. PubMed ID: 32219702
[TBL] [Abstract] [Full Text] [Related]
18. Systematic molecular profiling of inhibitor response to the clinical missense mutations of ErbB family kinases in human gastric cancer.
Ding X; Tong C; Chen R; Wang X; Gao D; Zhu L
J Mol Graph Model; 2020 May; 96():107526. PubMed ID: 31901678
[TBL] [Abstract] [Full Text] [Related]
19. A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer.
Kim TY; Han HS; Lee KW; Zang DY; Rha SY; Park YI; Kim JS; Lee KH; Park SH; Song EK; Jung SA; Lee N; Kim YH; Cho JY; Bang YJ
Gastric Cancer; 2019 Nov; 22(6):1206-1214. PubMed ID: 30945121
[TBL] [Abstract] [Full Text] [Related]
20. erbb4 promotes the proliferation of gastric cancer cells via the PI3K/Akt signaling pathway.
Xu J; Gong L; Qian Z; Song G; Liu J
Oncol Rep; 2018 Jun; 39(6):2892-2898. PubMed ID: 29620274
[TBL] [Abstract] [Full Text] [Related]
[Next]